Skip to main content

What the FDA labels say about taking them together

Rivastigmine and tolterodine

Rivastigmine's FDA label of June 19, 2024 names tolterodine in its drug interactions section; the tolterodine labels PlainMeds reads (2) do not name rivastigmine. The rivastigmine label: “Rivastigmine tartrate may increase the cholinergic effects of other cholinomimetic medications and may also interfere with the activity of anticholinergic medications.”

Check it at the source: the rivastigmine FDA label on DailyMed (effective June 19, 2024, Aurobindo Pharma Limited); the tolterodine FDA label on DailyMed (effective February 9, 2026, Torrent Pharmaceuticals Limited).

What does the rivastigmine label say about tolterodine?

Rivastigmine label, drug interactions

Rivastigmine tartrate may increase the cholinergic effects of other cholinomimetic medications and may also interfere with the activity of anticholinergic medications (e.g., oxybutynin, tolterodine).

Source: FDA drug label (Exelon, NDA022083), Sandoz Inc, effective May 8, 2024 (SPL set b6ed6d15-116d-4596-92ce-3414574d7ba0), via openFDA

Source: FDA drug label (Rivastigmine Tartrate), Aurobindo Pharma Limited, effective June 19, 2024 (SPL set c246a0e5-1e77-41ee-a7b3-384f21f2f2e0), via openFDA; the full label on DailyMed

What does the tolterodine label say about rivastigmine?

Tolterodine's label (effective February 9, 2026) and its 1 other brand-application label do not name rivastigmine in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (TOLTERODINE TARTRATE), Torrent Pharmaceuticals Limited, effective February 9, 2026 (SPL set db6e0b6d-0ce5-41d7-881f-881c11f530a4), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

18Rivastigmine generic labelers
14Tolterodine generic labelers
RivastigmineTolterodine
Labeled forAlzheimer's diseaseOveractive bladder
Boxed warningNoNo
Pharmacy cost (NADAC)$0.164 per capsule 1.5 mg capsule$0.268 per capsule 2 mg capsule
Shortage nowA presentation being discontinuedNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?